PMID- 28825180
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20210109
IS  - 1861-0293 (Electronic)
IS  - 1340-3443 (Linking)
VI  - 72
IP  - 1
DP  - 2018 Jan
TI  - Sansoninto as evidence-based remedial medicine for depression-like behavior.
PG  - 118-126
LID - 10.1007/s11418-017-1119-0 [doi]
AB  - In vitro screening methods using cultured Neuro2a cells to examine the activation 
      (phosphorylation) of extracellular signal-regulated kinase (ERK) 1/2 and 
      promotion of neurite outgrowth revealed that the extracts of 5 Kampo (Japanese 
      traditional) formulations have potential as medicines for the treatment of 
      behavioral abnormalities. Since sansoninto (SAT) extract exerted stronger effects 
      than the other candidates tested, we investigated whether its oral administration 
      ameliorates the pathologies of some mouse models of behavioral impairments. The 
      results obtained suggested that SAT extract exerted anti-depression-like effects 
      in the forced swim test, which may be mediated by the up-regulated expression of 
      brain-derived neurotrophic factor (BDNF) in the hippocampus. They may also be 
      mediated by the enhanced phosphorylation of the cAMP response element-binding 
      protein (CREB) via the mitogen-activated protein kinase (MAPK) cascade and 
      Ca(2+)/calmodulin-dependent protein kinase II (CaMK II) cascade, a downstream 
      signaling cascade of the N-methyl-D-aspartate (NMDA) receptor. These results 
      indicate that the extract of SAT has potential as a new remedial medicine in the 
      treatment of depression-like behavior.
FAU - Sawamoto, Atsushi
AU  - Sawamoto A
AD  - Department of Pharmacology, Graduate School of Clinical Pharmacy, Matsuyama 
      University, 4-2 Bunkyo-cho, Matsuyama, Ehime, 790-8578, Japan.
FAU - Okuyama, Satoshi
AU  - Okuyama S
AD  - Department of Pharmacology, Graduate School of Clinical Pharmacy, Matsuyama 
      University, 4-2 Bunkyo-cho, Matsuyama, Ehime, 790-8578, Japan. 
      sokuyama@g.matsuyama-u.ac.jp.
FAU - Amakura, Yoshiaki
AU  - Amakura Y
AD  - Department of Pharmacognosy, Graduate School of Clinical Pharmacy, Matsuyama 
      University, 4-2 Bunkyo-cho, Matsuyama, Ehime, 790-8578, Japan.
FAU - Yamada, Rie
AU  - Yamada R
AD  - Department of Pharmacognosy, Graduate School of Clinical Pharmacy, Matsuyama 
      University, 4-2 Bunkyo-cho, Matsuyama, Ehime, 790-8578, Japan.
FAU - Yoshimura, Morio
AU  - Yoshimura M
AD  - Department of Pharmacognosy, Graduate School of Clinical Pharmacy, Matsuyama 
      University, 4-2 Bunkyo-cho, Matsuyama, Ehime, 790-8578, Japan.
FAU - Nakajima, Mitsunari
AU  - Nakajima M
AD  - Department of Pharmacology, Graduate School of Clinical Pharmacy, Matsuyama 
      University, 4-2 Bunkyo-cho, Matsuyama, Ehime, 790-8578, Japan.
FAU - Furukawa, Yoshiko
AU  - Furukawa Y
AD  - Department of Pharmacology, Graduate School of Clinical Pharmacy, Matsuyama 
      University, 4-2 Bunkyo-cho, Matsuyama, Ehime, 790-8578, Japan.
LA  - eng
PT  - Journal Article
DEP - 20170819
PL  - Japan
TA  - J Nat Med
JT  - Journal of natural medicines
JID - 101518405
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Depression/*drug therapy
MH  - Japan
MH  - Male
MH  - Medicine, Kampo/*methods
MH  - Mice
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - Depression
OT  - Kampo medicine
OT  - Sansoninto
EDAT- 2017/08/22 06:00
MHDA- 2018/04/25 06:00
CRDT- 2017/08/22 06:00
PHST- 2017/03/14 00:00 [received]
PHST- 2017/07/30 00:00 [accepted]
PHST- 2017/08/22 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2017/08/22 06:00 [entrez]
AID - 10.1007/s11418-017-1119-0 [pii]
AID - 10.1007/s11418-017-1119-0 [doi]
PST - ppublish
SO  - J Nat Med. 2018 Jan;72(1):118-126. doi: 10.1007/s11418-017-1119-0. Epub 2017 Aug 
      19.